Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001380:Azauridine / Q000008:administration & dosage / Q000627:therapeutic use*; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000378:metabolism; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism; D007962:Leukocytes / Q000378:metabolism; D012075:Remission, Spontaneous; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D003561:Cytarabine; D014316:Tritium; D001380:Azauridine; D001215:Asparaginase; D013936:Thymidine